Rare Daily Staff

CAMP4 Therapeutics said it has entered into a research collaboration with Alnylam Pharmaceuticals to identify new druggable targets to address an undisclosed rare disease of the liver with a significant unmet need.

The collaboration brings together CAMP4’s expertise in pinpointing signaling targets that control the expression of genes with Alnylam’s expertise in RNAi therapeutics development to advance rare disease drug candidates.

“We are excited to partner with Alnylam given its leadership in the RNAi and liver disease space and our companies’ shared commitment to advancing new medicines to address critical unmet patient needs,” said Josh Mandel-Brehm, CEO of CAMP4.

Under the terms of the collaboration, CAMP4 will lead all activities to predict and validate disease-modifying targets in signaling pathways using its platform technology. Alnylam will lead in vivo proof-of-concept activities and may elect a target against which to develop RNAi therapies at the completion of the research term.

CAMP4 will receive an undisclosed upfront payment from Alnylam as well as milestone payments upon successful achievement of in vitro proof of concept and target election. CAMP4 is further eligible to receive development, approval and sales milestones plus royalties on products developed against the elected target.

 

January 24, 2019
Photo: Josh Mandel-Brehm, CEO of CAMP4